**Core tip:** We assess the antiviral effects of hepatitis B virus (HBV) S gene-specific anti-gene locked nucleic acid (LNA) in transgenic mice, to provide an experimental basis for gene therapy in patients with Chronic B-related Hepatitis. The inhibitory effect of anti-gene-LNA on serum HBV surface antigen (HBsAg) and HBV DNA peaked on day 7, with statistically significant differences compared with pre-treatment and control values. The mRNA levels of the HBVS gene and rates of HBsAg positive liver cells were significantly reduced compared with the control groups.

INTRODUCTION
============

Hepatitis B virus (HBV) is one of the most severe human infectious virus in the world. According to estimates, 240 million individuals globally are chronically infected with HBV\[[@B1]\]. In the past few years the prevalence of chronic HBV infection shows a declining trend throughout the world because of an anti-HBV vaccine and the implementation of successful immunization programs in enzootic zones. Despite improvement in global access to vaccination and treatment, mortality levels remain high\[[@B2],[@B3]\]. Chronic hepatitis B can be effectively and safely treated but a cure remains elusive.

The HBV genome is surrounded by an envelope containing HBV surface antigen (HBsAg) and HBV core antigen (HBcAg) and is a relaxed circular and partially double-stranded DNA\[[@B4]\]. In the nuclei of infected hepatocytes, covalently closed circular DNA (cccDNA) is compounded and sustained at low replication levels are infected with HBV; cccDNA plays a role as the transcription template for all HBV RNAs\[[@B5]\]. Due to cccDNA persistence in a stable form within the hepatocyte nucleus, it remains to a great extent unaffected by current therapies. One of the most important antiviral Drugs includes nucleus(t)ide analogues (NAs) and PEGylated/non-PEGylated interferon-alpha (IFN-α) are widely used to limit viral replication in chronic hepatitis B (CHB) infection\[[@B6]\]. NAs therapy *via* a direct effect on DNA polymerase activity to some extent notably reduces viral load\[[@B7]\]. Unfortunately, due to somewhat poor response and/or drug resistance, these therapies without achieve a therapeutic effect\[[@B8]\]. Therefore, the development of a novel therapeutic strategy to repress HBV replication is of great significance in saving lives of CHB patients.

Recently, anti-sense-LNA was shown to effectively inhibit HBV replication and expression *in vitro* models\[[@B9]\]. However, anti-sense therapy cannot cut off the replication and transcription of viral genes from the source. It can only interfere with the synthesis of viral protein at the level of expression, and is prone to stop drug rebound. In anti-gene therapy, triplex-forming oligonucleotides (TFOs) provides a promising approach to bind in the major groove of duplex DNA at polypurine or polypyrimidine stretches in a sequence-specific manner\[[@B10]\]. TFOs prevent the association of target DNA, polymerase, and transcription factors, down-regulating target genes\[[@B11]-[@B13]\]. A recent and promising technological progress is the development of locked nucleic acid (LNA), which not only enhances binding to its target sequence while being resistant to nuclease degradation, but also shows minimal toxicity\[[@B14]-[@B16]\]. Compared with anti-sense therapy, it has the advantage of blocking virus gene replication and transcription from the source.

The aim of this study was to design liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA express in transgenic mice, the final objective was to assess the antiviral effects of HBV S gene-specific anti-gene LNA in transgenic mice.

MATERIALS AND METHODS
=====================

Anti-gene-LNA synthesis and modification
----------------------------------------

According to the HBV S encoding chain, anti-gene-LNA was designed using the Walk function of the RNA structure software to select ΔG37 value of small fragments; by Blast analysis and homology sequence features, the synthesis and modification of anti-gene- LNA (5'-TaccTcTtgtA-3'; uppercase and lower case letters represent LNA and DNA, respectively) were performed by Shanghai biotechnology limited company.

Animals
-------

HBV transgenic mice (n = 35; 18 males and 17 females) weighing 19-23 g were purchased from the Guangzhou Military Air Force Hospital of the People's Liberation Army of China. All mice were positive for serum HBsAg and HBV DNA. They were bred and housed in pathogen-free conditions at 25 °C ± 2 °C under a 12 h:12 h light-dark cycle, with food and water provided ad libitum unless otherwise specified. All animal care and experimental procedures were approved by the Institutional Ethnics Committee of Youjiang Medical College for Nationalities.

Mice were randomly divided into five groups (*n* = 7 each), including negative control (blank control, unrelated sequence control), positive control (lamivudine, anti-sense-LNA), and anti-gene-LNA experimental group. The lamivudine control group was administered daily gavage of 2 mg/kg for 7 d; the remaining groups were injected (400 μL 5% glucose-liposome containing the corresponding drug) *via* the tail vein at 1, 3, and 5 d, respectively. Blood samples were collected from the orbital vein before and after injection on 3^rd^, 5^th^ and 7^th^ days, respectively, and centrifuged at 5000 r/min for 5min. The resulting serum was stored at -20 °C until use. On the 7^th^ day, all mice were sacrificed by cervical dislocation under anesthesia. Liver and kidney samples were obtained for histological assessments, ultrastructural examinations, and immunohistochemistry.

Measurement of serum HBsAg levels by enzyme-linked immune sorbent assay
-----------------------------------------------------------------------

Serum HBsAg levels were quantified with an enzyme-linked immune sorbent assay enzyme-linked immune sorbent assay (ELISA) kit according to the manufacturer's protocol. ELISA kits were purchased from Lizhu Biology Company, Zhuhai, China.

Measurement of HBV DNA levels by Fluorescence based PCR
-------------------------------------------------------

Serum HBV DNA levels were quantified with a diagnostic kit for the quantification of HBV DNA, according to the manufacturer's protocol. HBV DNA diagnostic kits were purchased from Daan Gene Company, Guangzhou, China. Briefly, 30 μL serum was added to 70 μL DNA extract and oscillated for 15 s, incubated at 100 °C for 10 min, and centrifuged at 12000 r/min for 5 min. Then, DNA samples (20 μL) were added to 30 μL of PCR reaction mix and centrifuged at 8000 r/min for 5 s. PCR was performed as follows: 93 °Cfor 2 min; 10 cycles of 93 °C for 45 s and 55 °Cfor 1 min; 30 cycles of 93 °Cfor 30 s and 55 °C for 45 s; 40 °Cfor 20 s. DNA levels were determined based on a standard curve for HBV.

Measurement of HBV S gene expression levels in the liver by reverse transcription polymerase chain reaction
-----------------------------------------------------------------------------------------------------------

Total RNA was extracted from liver samples with TRNzol Universal Reagent kit (TIANGEN), and concentrations were determined by spectrophotometry. Reverse transcription was performed with Fast Quant RT Kit (TIANGEN), according to the manufacturer's instructions. Briefly, RT was carried out in a final volume of 20 μL containing 5 × *g* DNA buffer (2 μL), Total RNA (1 μL), RNase-free ddH~2~O (7 μL) (incubated at 42 °C for 3 min), 10 × Fast RT buffer (2 μL), RT Enzyme Mix (1 μL), FQ-RT Primer Mix (2 μL), and RNase-Free ddH~2~O (5 μL), total 20 μL. The mixture was incubated at 42 °C for 15 min and 95 °C for 3 min. PCR amplification of the S gene was performed with the following primers: Forward, 5'-CTGCCTCTCCCTTATCGTCA-3'; Reverse, primer5'-TGGCAAGGACCCATAACTTC-3'.

The following temperature protocol was used: 94 °C for 3 min; 30 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min; 72 °C for 5 min. The amplicon was 830 bp. The glyceraldehyde phosphate dehydrogenase (GAPDH; reference gene) band in electrophoresis was used to determine the relative HBV S gene expression levels.

Immunohistochemistry
--------------------

To detect HBsAg in liver cells, the sections were dewaxed in xylene and rehydrated in graded alcohol. The endogenous peroxidase activity was suppressed by 3% hydrogen peroxide for 15 min. After rinsing twice in phosphate-buffered saline (PBS), antigen retrieval was performed by immersing the sections in 10 mmol/L sodium citrate buffer (pH 6.0) and heated for 15 min in a microwave oven. The sections were then treated for 4 °C for 18 h with mouse anti-HBsAg monoclonal antibody (1:100). PBS was used as a negative control. After three washes with PBS, the sections were subsequently treated with biotinylated goat anti-rabbit immunoglobulin for 15 min and horseradish peroxidase-streptavidin complex for 15 min. The slides were then washed three times with PBS and incubated in DAB for 5 min and counterstained with hematoxylin for 30 s. After dehydration with graded alcohol, the slides were mounted and analyzed under an Olympus BX53 inverted microscope (Olympus, Japan).

Histology
---------

To assess the morphological changes of the liver and kidney, formalin-treated tissue samples were paraffin embedded. Serial sections with 4 mm thickness were obtained and stained with hematoxylin and eosin (H and E). Observation was performed under an Olympus BX53 inverted microscope (Olympus, Japan).

Statistical analysis
--------------------

Quantitative data are mean ± SD, and were analyzed with the SPSS 13.0 software. Groups were compared by one-way analysis of variance (ANOVA) followed by the Tukey's multiple range post hoc test. P \< 0.05 was considered statistically significant.

RESULTS
=======

Serum HBsAg levels
------------------

The inhibitory effect on serum HBsAg was assessed by ELISA on the 3^rd^, 5^th^, and 7^th^ days, respectively, after treatment. Average rate reductions after treatment on the 3^rd^, 5^th^, and 7^th^ days were 32.34%, 45.96%, and 59.15%, respectively. The inhibitory effect of anti-gene-LNA on serum HBsAg peaked on day 7, with statistically significant differences compared with pre-treatment and control values (P \< 0.05). This suggests that anti-gene-LNA significantly inhibited HBsAg in mice in a time-dependent manner (Table [1](#T1){ref-type="table"} and Figure [1A](#F1){ref-type="fig"}).

###### 

Serum hepatitis B surface antigen levels in transgenic mice (*n* = 7, mean ± SD)

  **Groups**   **Before treatment**   **After treatment**                                                                                                                                                                
  ------------ ---------------------- --------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Blank        2.34 ± 0.22            2.33 ± 0.23           2.32 ± 0.31                                                                    2.37 ± 0.30                                                                   2.35 ± 0.21
  USQ          2.35 ± 0.36            2.34 ± 0.25           2.37 ± 0.31                                                                    2.31 ± 0.45                                                                   2.36 ± 0.38
  LAM          2.33 ± 0.28            2.31 ± 0.38           2.27 ± 0.24                                                                    2.21 ± 0.23                                                                   2.15 ± 0.19
  Anti-S-LNA   2.31 ± 0.27            2.03 ± 0.28           1.61 ± 0.11                                                                    1.55 ± 0.16                                                                   1.33 ± 0.26
  Anti-G-LNA   2.35 ± 0.33            1.92 ± 0.40           1.59 ± 0.32 [a](#T1FN1){ref-type="table-fn"}[b](#T1FN2){ref-type="table-fn"}   1.27 ± 0.29[a](#T1FN1){ref-type="table-fn"}[b](#T1FN2){ref-type="table-fn"}   0.96 ± 0.18[a](#T1FN1){ref-type="table-fn"}[b](#T1FN2){ref-type="table-fn"}[c](#T1FN3){ref-type="table-fn"}

Indicates significant differences between pre-treatment *vs* Anti-G-LNA (*P* \< 0.05);

Indicates significant differences between Blank, USQ, LAM group *vs* Anti-G-LNA (*P* \< 0.05);

Indicates significant differences between Anti-S-LNA *vs* Anti-G-LNA (*P* \< 0.05). Values are mean ± SD. Blank: Blank control group, 5% glucose-liposome administered by tail vein injection; USQ: Unrelated sequence; LAM: Lamivudine; Anti-S-LNA: Anti-sense-LNA; Anti-G-LNA: Anti-gene-LNA; LNA: Locked nucleic acid.

![Inhibition of hepatitis B virus deoxyribonucleic acid and hepatitis B surface antigen by anti-gene-locked nucleic acid, anti-sense-locked nucleic acid, and lamivudine. A: The inhibition rate of HBsAg; B: The inhibition rate of hepatitis B virus (HBV) deoxyribonucleic acid. ^a^Significant (*P* \< 0.05) HBsAg and HBV DNA expression alterations between lamivudine, anti-sense-LNA *vs* anti-gene-LNA. Values are mean ± SD. LNA: Locked nucleic acid; HBsAg: HBV surface antigen.](WJCC-6-183-g001){#F1}

HBV DNA levels
--------------

The inhibitory effect of anti-gene-LNA on HBV DNA was analyzed by fluorescence based PCR on the 3^rd^, 5^th^, and 7^th^ days after treatment, respectively. Average reduction rates on the 3^rd^, 5^th^, and 7^th^ days were 38.55%, 50.95%, and 62.26%, respectively. This inhibitory effect peaked on the 7^th^ day after treatment with anti-gene-LNA, with statistically significant differences compared with pre-treatment and control values (P \< 0.05). This suggests that anti-gene-LNA significantly inhibits HBV DAN in mice in a time-dependent manner (Table [2](#T2){ref-type="table"} and Figure 1B)

###### 

Effects of anti-gene-locked nucleic acid on hepatitis B virus deoxyribonucleic acid replication and expression in transgenic mice (*n* = 7, mean ± SD; × 10^3^ IU/mL)

  **Groups**   **Before treatment**   **After treatment**                                                                                                                                                               
  ------------ ---------------------- --------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Blank        10.81 ± 1.15           10.80 ± 0.78          10.86 ± 1.85                                                                  10.80 ± 1.19                                                                  10.77 ± 1.25
  USQ          11.12 ± 0.87           11.25 ± 0.94          11.16 ± 0.96                                                                  11.06 ± 0.85                                                                  11.08 ± 0.89
  LAM          10.96 ± 1.08           10.93 ± 1.12          10.62 ± 0.89                                                                  10.07 ± 1.37                                                                  9.73 ± 1.17
  Anti-S-LNA   10.92 ± 1.09           8.94 ± 0.89           6.91 ± 1.26                                                                   5.48 ± 0.97                                                                   5.79 ± 0.92
  Anti-G-LNA   11.05 ± 1.25           9.12 ± 0.96           6.79 ± 1.16[a](#T2FN1){ref-type="table-fn"}[b](#T2FN2){ref-type="table-fn"}   5.42 ± 1.12[a](#T2FN1){ref-type="table-fn"}[b](#T2FN2){ref-type="table-fn"}   4.17 ± 1.29[a](#T2FN1){ref-type="table-fn"}[b](#T2FN2){ref-type="table-fn"}[c](#T2FN3){ref-type="table-fn"}

Indicates significant differences between pre-treatment *vs* Anti-G-LNA (*P* \< 0.05);

Indicates significant differences between Blank, USQ, LAM group *vs* Anti-G-LNA (*P* \< 0.05);

Indicates significant differences between Anti-S-LNA *vs* Anti-G-LNA (*P* \< 0.05). Values are mean ± SD. Blank: Blank control group, 5% glucose-liposome administered by tail vein injection; USQ: Unrelated sequence; LAM: Lamivudine; Anti-S-LNA: Anti-sense-LNA; Anti-G-LNA: Anti-gene-LNA; LNA: Locked nucleic acid.

HBV S gene expression levels in the liver
-----------------------------------------

The average grayscale values of lanes 1-5 for HBV S-DNA (with GAPDH set to 1) were 1, 0.96, 0.78, 0.51, and 0.32, respectively. Quantitation of HBV S gene expression levels in the liver after treatment with anti-gene-LNA revealed a significant decrease compared with pre-treatment (P \< 0.05) or control (P \< 0.05) values (Figure [2](#F2){ref-type="fig"}).

![Hepatitis B virus S-mRNA expression levels in the liver of transgenic mice (mean ± SD, *n* = 7). A: Electrophoregram showing HBV S and GAPDH bands; B: Relative expression levels of HBV S-mRNA. ^a^Significant (P \< 0.05) S-mRNA expression alterations between blank (1), unrelated sequence (2), lamivudine (3) *vs* Anti-sense-LNA (4) and Anti-gene-LNA (5); ^c^Significant (P \< 0.05) S-mRNA expression alterations between Anti-sense-LNA (4) *vs* Anti-gene-LNA (5). Values are mean ± SD. M: DNA marker; LNA: Locked nucleic acid; HBV: Hepatitis B virus.](WJCC-6-183-g002){#F2}

HBsAg positive cells in liver tissues
-------------------------------------

Figure [3](#F3){ref-type="fig"} shows representative immunohistochemical staining data for HBsAg positive cells in liver tissues. No significant differences were observed in the rates of HBsAg positive liver cells among the blank control, unrelated sequence control and lamivudine control groups. Meanwhile, 47% of liver cells were positive for HBsAg after treatment with anti-sense-LNA verify, a rate significantly lower than those of the blank control, unrelated sequence control, and lamivudine control groups (P \< 0.05); the positive expression rate of HBsAg in liver cells in the anti-gene-LNA treatment group was 31%, significantly lower than those of all control groups (P \< 0.05)

![Immunohistochemical detection (× 200) of hepatitis B surface antigen positive cells in liver tissues of transgenic mice. ^a^Significant (P \< 0.05) HBsAg positive cells expression alterations between blank (A),unrelated sequence (B), lamivudine (C) *vs* anti-sense-LNA (D) and anti-gene-LNA (E); ^c^Significant (*P* \< 0.05) HBsAg positive cells expression alterations between anti-sense-LNA (D) *vs* anti-gene-LNA (E). Values are mean ± SD; F: Positive HBsAg cells. LNA: Locked nucleic acid; HBV: Hepatitis B virus; HBsAg: HBV surface antigen.](WJCC-6-183-g003){#F3}

Histological observations
-------------------------

H&E staining was used to assess the effects of anti-gene-LNA and liposomes on the histological features of the liver and kidney. Liver and kidney sections stained with H and E showed no significant differences between the anti-gene-LNA group and controls, suggesting that anti-gene-LNA had no obvious toxicity on liver and kidney at the histological level (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Morphological changes in liver sections obtained from transgenic mice infected with hepatitis B virus. Mice were sacrificed, and the livers were harvested and prepared for observation on the 7^th^ d after treatment. A: Blank control group; B: Unrelated sequence control group; C: Lamivudine control group; D: Anti-sense-LNA treatment control group; E: Anti-gene-LNA treatment group. Liver sections were stained with hematoxylin and eosin (original magnification, × 200). There were no significant morphological changes in the liver among groups. LNA: Locked nucleic acid.](WJCC-6-183-g004){#F4}

![Morphological changes in kidney sections obtained from transgenic mice infected with hepatitis B virus. Mice were sacrificed, and the kidneys were harvested and prepared for observation on the 7^th^ d after treatment. A: Blank control group; B: Unrelated sequence control group; C: Lamivudine control group; D: Anti-sense-LNA treatment control group; E: Anti-gene-LNA treatment group. Kidney sections were stained with hematoxylin and eosin (original magnification, × 200). There were no significant morphological changes in the kidney among groups. LNA: Locked nucleic acid.](WJCC-6-183-g005){#F5}

DISCUSSION
==========

The present study assessed serum HBsAg, HBV DNA, and HBV S gene expression levels in transgenic mice. The results demonstrated that HBV amounts were significantly reduced after injection of anti-gene- LNA on 7^th^ day, shows a significant difference compared with before treatment and control groups (P \< 0.05). Significantly less positive HBsAg cells in liver tissues were obtained after treatment with anti-gene-LNA compared with the control groups, indicating that anti-gene-LNA transacted by cationic liposomes can effectively enter nucleolus in the liver of transgenic mice after tail vein injection and play a role in reducing HBV DNA replication and transcription.

We successfully used anti-sense-LNA to inhibit the translation and expression of HBV mRNA in vitro and in vivo models in previous study\[[@B15]\], due to the basic principle of anti-sense-LNA targeting specific mRNAs by annealing complementary oligonucleotides\[[@B17]-[@B20]\]. In the simplest form, anti-sense-LNAs are introduced into the liver cell to down-regulate gene expression by interfering with the translation of mRNA instead of DNA transcription, *i.e*., they are involved in posttranscriptional rather than transcriptional gene regulation. Therefore, treatment with anti-sense-LNA does not achieve satisfactory effects. TFOs have emerged as potential regulators of biological activity for direct modifications of genomic DNA at selected sites through mutagenesis or homologous recombination and changing the anti-gene therapeutic method\[[@B21]-[@B23]\]. In the present study, anti-gene-LNA was assessed for its antiviral effects in transgenic mice. The results showed that the inhibitory effect of anti-gene-LNA peaked on the 7^th^ day, with a statistically significant difference compared with the anti-sense-LNA group (*P* \< 0.05). However, compared with other nucleic acid-based approaches, TFOs faces challenges such as oligonucleotides (ONs) targeting ability and the stability of the TFOs in a genomic context. In order to efficient, ON should increase target DNA selectively, easily, stability, and with high affinity. Until now, due to the low of affinity of TFOs or their DNA targets, the method of anti-gene-DNA hampered to down-regulate and control the expression level of genomic DNA. The anti-gene-LNA sugar unit not only significantly enhances triplex stability but also partly relieves sequence restriction constraints\[[@B24]-[@B26]\]. The present study provided evidence that once in the nucleus, an integrated HBV DNA sequence composed of LNA and DNA oligonucleotides (anti-gene-LNA) effectively targeted HBV, therefore inhibiting its replication at the transcription level.

HBV DNA is easily mutated compared to other DNA viruses during replication; one of the important reasons is that HBV DNA polymerase lacks a proofreading function\[[@B27]\], which can cause HBV mutations to occur at a 10-fold higher frequency\[[@B28]\]. This results in decreased susceptibility or increased resistance in anti-HBV treatment. HBV contains 4 overlapping open reading frames (ORFs) encoding the polymerase (P), core (C), surface antigen (S), and X proteins\[[@B29]\]. The S gene region is one of the most important open reading frames of the HBV genome, encoding a protein forming an important part of HbsAg\[[@B30],[@B31]\]. Thus, the S gene is not only closely associated with virus replication, transcription, assembly, and secretion processes, but also with cellular and humoral immune responses induced by the virus.

Taken together, this study showed an effective strategy that with liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA expression in transgenic mice. The new treatment strategy of repressing HBV DNA replication is usefulness and worth further studying. Based on the data presented herein highlight the usefulness of anti-gene-LNA mediated silencing HBV DNA replication and transcription bring forth innovative ideas and potentially viable tool for gene therapy.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Hepatitis B virus (HBV) is one of the most severe human pathogens. It is reported that 240 million individuals globally are chronically infected with HBV and current antivirals cannot clear the infection or adequately suppress disease.

Research motivation
-------------------

Despite improvement in global access to vaccination and treatment, mortality levels remain high. Chronic hepatitis B can be effectively and safely treated but a cure remains elusive.

Research objectives
-------------------

The aim of this study is to inhibit HBV DNA expression with anti-gene locked nucleic acid (LNA) in transgenic mice.

Research methods
----------------

The aim of this study was to design liposome based transport of a LNA modified oligonucleotide to inhibit HBV DNA express in transgenic mice, the final objective was to assess the antiviral effects of HBV S gene-specific anti-gene LNA in transgenic mice.

Research results
----------------

Average rate reductions of HBsAg, HBV DNA, mRNA levels of the HBV S gene and the rate of HBsAg positive liver cells, with statistically significant differences compared with pre-treatment and control values (*P* \< 0.05 for all). Liver and kidney function, and histology showed no abnormalities.

Research conclusions
--------------------

Anti-gene-LNA transacted by cationic liposomes can effectively enter nucleolus in the liver of transgenic mice after tail vein injection and play a role in reducing HBV DNA replication and transcription.

Research perspectives
---------------------

Based on the data presented herein highlight the usefulness of anti-gene-LNA mediated silencing HBV DNA replication and transcription bring forth innovative ideas and potentially viable tool for gene therapy.
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